Abstract
The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.
Keywords: Cell, Cancer, Cetuximab, Food and Drug Association, Cytotoxic T lymphocytes, Epidermal growth factors.
Graphical Abstract
Current Topics in Medicinal Chemistry
Title:Cetuximab and the Head and Neck Squamous Cell Cancer
Volume: 18 Issue: 3
Author(s): Riccardo Concu*M. Natalia D.S. Cordeiro*
Affiliation:
- REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto,Portugal
- REQUIMTE, Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua do Campo Alegre, 687, 4169-007 Porto,Portugal
Keywords: Cell, Cancer, Cetuximab, Food and Drug Association, Cytotoxic T lymphocytes, Epidermal growth factors.
Abstract: The Head and Neck Squamous Cell Cancer (HNSCC) is the most common type of head and neck cancer (more than 90%), and all over the world more than a half million people have been developing this cancer in the last years. This type of cancer is usually marked by a poor prognosis with a really significant morbidity and mortality. Cetuximab received early favor as an exciting and promising new therapy with relatively mild side effect, and due to this, received authorization in 2004 from the European Medicines Agency (EMA) and in 2006 from the Food and Drug Association (FDA) for the treatment of patients with squamous cell cancer of the head and neck in combination with radiation therapy for locally advanced disease. In this work we will review the application and the efficacy of the Cetuximab in the treatment of the HNSCC.
Export Options
About this article
Cite this article as:
Concu Riccardo *, Cordeiro Natalia D.S. M. *, Cetuximab and the Head and Neck Squamous Cell Cancer, Current Topics in Medicinal Chemistry 2018; 18 (3) . https://dx.doi.org/10.2174/1568026618666180112162412
DOI https://dx.doi.org/10.2174/1568026618666180112162412 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
MICA Gene and Relevance to Immune Responses in Organ Transplants and Inflammatory, Tumoral and Autoimmune Diseases
Current Immunology Reviews (Discontinued) Transmucosal Drug Delivery- An Overview
Drug Delivery Letters Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Current Medicinal Chemistry Redox Regulation in the Base Excision Repair Pathway: Old and New Players as Cancer Therapeutic Targets
Current Medicinal Chemistry Comparison with Naloxone of Two Dynorphin a Analogues with K- and δ-Opioid Antagonist Activity
Medicinal Chemistry Adenosine and the Auditory System
Current Neuropharmacology Cancer Diagnosis and Treatment Guidance: Role of MRI and MRI Probes in the Era of Molecular Imaging
Current Pharmaceutical Biotechnology Design of Peptide Imaging Agents for Whole-body and Intraoperative Molecular Imaging
Current Medicinal Chemistry Recent Advances in Metabolomics
Current Metabolomics Emerging Multi-cancer Regulatory Role of ESRP1: Orchestration of Alternative Splicing to Control EMT
Current Cancer Drug Targets Targeting the Fibroblast Growth Factor Receptors for the Treatment of Cancer
Anti-Cancer Agents in Medicinal Chemistry Meet Our Editorial Board Member
Current Stem Cell Research & Therapy Bladder Cancer and Stem Cells
Current Signal Transduction Therapy Epigenetic Regulation of Epithelial-Mesenchymal Transition by Hypoxia in Cancer: Targets and Therapy
Current Pharmaceutical Design Thalidomide–A Notorious Sedative to a Wonder Anticancer Drug
Current Medicinal Chemistry MicroRNA in the Pathogenesis and Prognosis of Esophageal Cancer
Current Pharmaceutical Design New Developments in Systemic Therapy for Hepatocellular Carcinoma
Current Cancer Therapy Reviews The Holy Grail of Polymer Therapeutics for Cancer Therapy: An Overview on the Pharmacokinetics and Bio Distribution
Current Drug Metabolism Cellular and Physiological Effects of Arginine
Mini-Reviews in Medicinal Chemistry Genetics and Genomics of Hepatic Acute Phase Reactants: A Mini-Review
Inflammation & Allergy - Drug Targets (Discontinued)